On January 17th, HIPRA PORTUGAL introduced YURVAC® RHD, the first recombinant vaccine against RHD indicated for protection against rabbit haemorrhagic disease caused by both the classic and variant strains, including highly virulent strains. The event took place at Hotel Borralha - Restaurant & Spa in Vila Real, where over 40 professionals from the rabbit farming sector, including producers, veterinarians, and important researchers, gathered.

The launch began with an institutional presentation by Alexandre Domingues, BUM Rabbits at HIPRA PORTUGAL, regarding the growth and vision of HIPRA in the rabbit farming sector.

Following this, Filipe Pinto, Sales Representative at HIPRA PORTUGAL, explained the key concepts of RHDV, highlighted HIPRA's historical responses to the virus, and presented how the new vaccine YURVAC® RHD is produced.

Finally, Filipe Pinto, along with Sandra Gascon, Global Product Manager at HIPRA, addressed all the preclinical and clinical studies conducted during the development and registration of YURVAC® RHD.

The launch concluded with a lunch, during which participants had the opportunity to exchange work experiences and ask more detailed questions about our new vaccine.

Among its numerous advantages, YURVAC® RHD is the first commercial veterinary vaccine that uses yeast as a technological platform to recombinantly produce the RHD virus capsid protein in the form of VLPs (virus-like particles). Additionally, it is also the first RHD vaccine indicated for protection against highly virulent RHDV2 strains and provides cross-protection against classic (RHDV) strains.

With this launch, HIPRA reaffirms its position as a leader in Portugal in controlling rabbit haemorrhagic disease, while continuing its commitment to strengthening rabbit vaccination plans.